Androgen Deprivation Therapy Linked With Increased Risk of Dementia

Share this content:
Androgen deprivation therapy for the treatment of prostate cancer may be associated with an increased risk for dementia.
Androgen deprivation therapy for the treatment of prostate cancer may be associated with an increased risk for dementia.

Androgen deprivation therapy (ADT) for the treatment of prostate cancer may be associated with an increased risk for dementia, according to a study published in JAMA Oncology.1

Researchers led by Kevin Nead, MD, MPhil, of Stanford University School of Medicine in California conducted a cohort study of 9272 men with prostate cancer who were analyzed for their electronic medical record data using a text-processing method.

The study's authors tested for the potential risk of dementia from ADT through propensity score-matched Cox proportional hazards regression models and Kaplan-Meier survival analysis.

The researchers found a statistically significant association between ADT use and risk for dementia, with similar results when excluding patients with Alzheimer disease upon sensitivity analyses.

RELATED: Ipilimumab Fails to Improve Overall Survival in mCR Prostate Cancer

Absolute increased risk for developing dementia among patients who received ADT was 4.4% at 5 years, and individuals with at least 12 months of ADT use had the greatest absolute increased risk for dementia upon stratification by duration of ADT.

Patients undergoing ADT who were 70 years or older had the highest cumulative probability of developing dementia, according to Kaplan-Meier analysis.

Reference

  1. Nead KT, Gaskin G, Chester C, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2016 Oct 13. doi:10.1001/jamaoncol.2016.3662 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters